Drugs reported effective |
Remdesivir |
Broad-spectrum RNA
† virus antiviral drug (SARS/MERS/Ebola) |
Pre-terminate the RNA chains of the virus before mature |
Infecting
cells: EC50=0·77μM, EC90=1·76μM. Involving one treatment in America and
France respectively, both patients had been cured. |
(Dealmoon, 2020;
Holshue et al., 2020; M. Wang et al., 2020) |
|
Chloroquine |
Treats Malarial and
autoimmune disease |
Escalating the endosomal PH¶ to
inhibit cell fusion |
Infecting cells: EC50=6·90μM, EC90=1·13μM. 100
cases of patient treated, considerable effect had shown and no adverse
reaction was reported. |
(M. Wang et al., 2020; YSA,
2020) |
|
Hydroxychloroquine |
Treats
Systemic lupus erythematosus |
Escalating the endosomal
PH¶ to inhibit cell fusion |
20 cases of patients
treated, significant improvement in 19 cases |
(Publish,
2020) |
|
Favipiravir |
Anti-Influenza |
Inhibits the RNA-dependent RNA
polymerase of RNA viruses |
Infecting cells: EC50=61·88μM. Further
evaluation of SARS-CoV-2 had been conducted. |
(Clercq, 2020; M. Wang et
al., 2020) |
|
Arbidol |
Anti-Influenza |
Interferes the cell membrane’s fusion with
the virus. |
Abidol at a concentration of 10 to 30 micromolar can
effectively inhibit coronavirus up to 60 times compared with a
drug-untreated control group |
(qi, 2020) |
|
Darunavir |
Anti-HIV ‡
|
Prevents virus from using
the ribosomes of the host cell to synthesize proteins needed by the
virus (But its mechanism on against
SARS-CoV-2
is still unknown) |
at a concentration of 300 micromolar, darunavir can
significantly inhibit virus replication |
(qi, 2020) |
|
Chinese Traditional Medicine |
·· |
·· |
214 confirmed cases had shown an over 90% rate of effective,
of which the symptoms of 60% of patients experienced significant
improvement, 30% of patients with stable symptoms without exacerbation |
(Ping;, 2020) |